Navicixizumab (Anti-DLL4)Navicixizumab (Anti-DLL4)
Move your mouse over image or click to enlarge

Navicixizumab (Anti-DLL4)

Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD.
Cat# Size Price Qty Buy
A2519-1mg*25 1mg*25
£4,152.00
A2519-1mg*5 1mg*5
£1,384.00
A2519-1mg 1mg
£441.00

Additional Information

Property Value or Rating
Manufacturer Selleck Chemicals LLC
Manufacturer Cat# A2519

Related Documents